Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cumberland Pharmaceuticals Inc. (CPIX) and Encourages Stockholders to Learn More About the Investigation

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / November 5, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cumberland Pharmaceuticals Inc. ("Cumberland" or "the Company") (NASDAQ:CPIX). Investors who purchased Cumberland securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/cumberland-pharmaceuticals-inc-cpix-investigation.

Cumberland Investigation Details

On October 23, 2026, Cumberland announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). While the Company emphasized that the drug was well tolerated and achieved its primary safety objective, observers noted that the pilot study offered no clear efficacy signal. Because a majority of subjects in both the treatment and placebo groups experienced limited disease progression during the study, the 41-patient trial lacked the statistical power to detect a meaningful treatment difference, rendering efficacy conclusions impossible. On this news, Cumberland's stock price fell $4.14 per share, or 48.76%, to close at $4.35 per share on October 26, 2026.

What's Next for Cumberland Investors?

If you are aware of any facts relating to this investigation or purchased Cumberland securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/cumberland-pharmaceuticals-inc-cpix-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Cumberland Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Cumberland Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.